What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.

Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.

Hers provides prescription medication and support for weight loss, hair growth, sexual health, and more. Learn more about this telehealth company.

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior ...

Hims & Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million. The company said it continues to expect full-year 2025 revenue in the ...